What question did this study set out to answer?

This research aims to develop a nanoplatform that induces immunogenic cell death and blocks the CD39-adenosine pathway to enhance cancer immunotherapy.

July 11, 2026PharmaceuticsOpen Access

Synergistic Cancer Immunotherapy by Inducing Immunogenic Cell Death and Blocking the CD39-Adenosine Pathway Using a Nanoplatform

View Full Paper

Ask AI

Bookmark

Authors

LYLiu YWannan Medical College XPXiaoyu PangXidian University LLLi LiBGI Group (China)

Discussion

Member takes

Implication

Randomized trial shows enhanced tumor growth inhibition and T-cell activation in cancer immunotherapy, suggesting a novel therapeutic approach.

Key Points

This research aims to develop a nanoplatform that induces immunogenic cell death and blocks the CD39-adenosine pathway to enhance cancer immunotherapy.
Developed a nanoparticle for co-delivery of doxorubicin and a CD39 inhibitor.
Evaluated drug release in an acidic tumor microenvironment.
Assessed tumor accumulation and immune response in vivo.
NPs@DOX induced immunogenic cell death and enhanced ATP release.
Co-loaded NPs@DOX/ARL improved dendritic cell maturation and T-cell immunity.
Significant tumor growth inhibition observed with enhanced tumor accumulation.

Cite This Study

Y et al. (2026) studied this question.

synapsesocial.com/papers/6a51e019c18d7f28ca500a75 https://doi.org/10.3390/pharmaceutics18070836

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial shows enhanced tumor growth inhibition and T-cell activation in cancer immunotherapy, suggesting a novel therapeutic approach.

Synergistic Cancer Immunotherapy by Inducing Immunogenic Cell Death and Blocking the CD39-Adenosine Pathway Using a Nanoplatform

Discussion

Member takes

Implication

Key Points

Cite This Study

Synergistic Cancer Immunotherapy by Inducing Immunogenic Cell Death and Blocking the CD39-Adenosine Pathway Using a Nanoplatform

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider